Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBT (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of EBT data on record, last reported at -$6.2 million in Q4 2025.

  • For Q4 2025, EBT rose 72.97% year-over-year to -$6.2 million; the TTM value through Dec 2025 reached -$64.2 million, up 43.43%, while the annual FY2025 figure was -$64.4 million, 44.3% up from the prior year.
  • EBT reached -$6.2 million in Q4 2025 per TARS's latest filing, up from -$12.7 million in the prior quarter.
  • Across five years, EBT topped out at $10.7 million in Q1 2021 and bottomed at -$42.5 million in Q4 2023.
  • Average EBT over 5 years is -$19.4 million, with a median of -$21.3 million recorded in 2022.
  • Peak YoY movement for EBT: skyrocketed 647.93% in 2021, then crashed 420.98% in 2023.
  • A 5-year view of EBT shows it stood at -$14.4 million in 2021, then increased by 5.61% to -$13.6 million in 2022, then tumbled by 211.62% to -$42.5 million in 2023, then surged by 45.63% to -$23.1 million in 2024, then surged by 72.97% to -$6.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$6.2 million in Q4 2025, -$12.7 million in Q3 2025, and -$20.2 million in Q2 2025.